Regeneron Pharmaceuticals Inc

REGN is in a Stage 2 advancing uptrend confirmed by a recent momentum breakout. Price is holding above rising short-term EMAs and the 50-DMA with no visible exhaustion, supporting further continuation. Short-term conditions favor immediate entry as pullbacks into the 9/20 EMA zone are absorbing, so we will Buy Now on a shallow retracement into the rising EMA support area to align with fresh demand.

• ↑Q1 2026 revenues $3.6B (+19% YoY); Dupixent net sales $4.9B (+31% YoY).
• ↑Pipeline holds ~45 candidates; management expects ≥4 FDA approvals this year.
• ↓FDA review delay for ILEA-HD pre-filled syringe may push back launch.